RxDoctor Payments Data

Angela Falany, MD

Obstetrics & Gynecology · Woodstock, GANPI 1780670554

Payments from drug & device makers

$3,119in general payments, 2019–2025

Across 132 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$862
  • AbbVie$386
  • Sumitomo Pharma America, Inc.$248
  • Pfizer$199
  • Nuwellis, Inc.$193
  • Astellas Pharma US Inc$162
  • plus $1K from 36 others
$413in research payments, 2019–2025

Across 1 payment — averaging $412.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$413

What the payments were for

  • Travel & lodging$2909%
  • Food & beverage$2,81490%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,119 in reported general payments places this provider in the 80th percentile of 1,324 obstetrics & gynecology providers in Georgia.

See all obstetrics & gynecology providers in Georgia

Medicare billing

Part B allowed, 2024
$92,524
Medicare patients
148
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron77$44,775
GemtesaVibegron37$21,380
Estradiol122$10,019
LinzessLinaclotide13$6,660
YuvafemEstradiol11$1,754
ProgesteroneProgesterone, Micronized42$1,172
Clobetasol Propionate31$887
DottiEstradiol12$807
Estradiol (Twice Weekly)Estradiol16$779
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst25$753
Fesoterodine Fumarate ErFesoterodine Fumarate17$692
Venlafaxine Hcl ErVenlafaxine Hcl19$503
Oxybutynin Chloride ErOxybutynin Chloride12$226
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen38$221
Gabapentin16$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$162$44,77577 claims
Sumitomo Pharma America, Inc.Gemtesa$248$21,38037 claims
AbbVieLinzess$386$6,66013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,324 obstetrics & gynecology providers in Georgia.

Other obstetrics & gynecology in Woodstock

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →